|
|
Yavuz Silay M.D. , CCRP
Director, Scientific and Medical Affairs, Teva Neuroscience, Inc
International Pharmaceutical Executive", "Business, Strategy, Marketing Savvy Physician Scientist"
|
add to contacts
interests
1 contact
positions
current
Director, Scientific and Medical Affairs, Teva Neuroscience, Inc, Kansas City, Missouri, United States
May 2009-
education
Executive MBA (Master of Business Administration), Washington University in St. Louis, St. Louis, Missouri, United States
2008-
"Marketing, Strategy, Leadership"
M.D., Ankara University, Ankara, Turkey
1993-2000
awards and honors
Received permanent residency through "Outstanding researcher category"
research summary
Scientific Experience—As a business driven physician scientist, 10 years of clinical and research experience in Neurology and related therapeutic areas within academics and industry. Very familiar and experienced in the clinical drug development, KOL interactions, advisory board meetings, CME development, speaker training, publication planning, regulatory processes, designing and conducting clinical trials. Strong practical grasp of health economics and outcomes research as it applies to achieving strategic business goals.
Ability to inspire —By creating a dynamic environment that fosters transparency, collaboration and innovative thinking across the organization.
Proven track-record of success-- working across functions in a matrix environment with strong people management skills and an ability to foster teamwork across functions.
Proven track record of scientific publications—As a prolific physician scientist published more than 15 peer reviewed articles cited in pubmed and presented in more than 50 national / international scientific and industry meetings.
Strong project and process management-- Orientation and be able to drive multiple projects through effective motivation and collaboration; able to think through complex systems, and be able to see
the vision and align/simplify these systems to achieve this vision.
Business Savvy & Drive-- As a current executive MBA student in training, providing quantifiable results in identifying business opportunities, develops a strategic plan, gaining buy-in and driving execution to capture those opportunities.
“Gets it done” Attitude—As a practical thinker and genuine team player, while providing direction , able to identify simple, realizable solutions; identify and alleviate any potential hurdles to achieve corporate objectives.
International Focus – Perceived as a world citizen in a global village, therefore has strong ability to interact on a regular basis with other organizations with different corporate cultures (such as TEVA organizations in North America, Israel and Europe, Ther-Rx, ETHEX, Forest Pharmaceutical organizations, in U.S. and Europe as well as Lundbeck)
Internal Medicine(Pulmonary & Critical Care, Asthma, Cystic fibrosis, Sarcoidosis, lung transplant, Diabetic Neuropathy), Neurology ( Movement disorders, Parkinson's, Huntington's, Tourette, DBS, Alzheimer, Autism,Epilepsy), Psychiatry(Schizophrenia,Bipolar), Pain ( Fibromyalgia, Osteoarthritis), CFS, GI (antiemetics), Growth Hormone, Oncology, Women's health, anemia, Head Trauma from Preclinical to postmarketing
Ability to inspire —By creating a dynamic environment that fosters transparency, collaboration and innovative thinking across the organization.
Proven track-record of success-- working across functions in a matrix environment with strong people management skills and an ability to foster teamwork across functions.
Proven track record of scientific publications—As a prolific physician scientist published more than 15 peer reviewed articles cited in pubmed and presented in more than 50 national / international scientific and industry meetings.
Strong project and process management-- Orientation and be able to drive multiple projects through effective motivation and collaboration; able to think through complex systems, and be able to see
the vision and align/simplify these systems to achieve this vision.
Business Savvy & Drive-- As a current executive MBA student in training, providing quantifiable results in identifying business opportunities, develops a strategic plan, gaining buy-in and driving execution to capture those opportunities.
“Gets it done” Attitude—As a practical thinker and genuine team player, while providing direction , able to identify simple, realizable solutions; identify and alleviate any potential hurdles to achieve corporate objectives.
International Focus – Perceived as a world citizen in a global village, therefore has strong ability to interact on a regular basis with other organizations with different corporate cultures (such as TEVA organizations in North America, Israel and Europe, Ther-Rx, ETHEX, Forest Pharmaceutical organizations, in U.S. and Europe as well as Lundbeck)
Internal Medicine(Pulmonary & Critical Care, Asthma, Cystic fibrosis, Sarcoidosis, lung transplant, Diabetic Neuropathy), Neurology ( Movement disorders, Parkinson's, Huntington's, Tourette, DBS, Alzheimer, Autism,Epilepsy), Psychiatry(Schizophrenia,Bipolar), Pain ( Fibromyalgia, Osteoarthritis), CFS, GI (antiemetics), Growth Hormone, Oncology, Women's health, anemia, Head Trauma from Preclinical to postmarketing
research projects
SELECTED SCIENTIFIC PRESENTATIONS AND PUBLICATIONS
• Drug eluting stents for acute myocardial infarction. Yeter E, Kurt M, Silay Y, HV Anderson, Denktas AE, Expert Opinion in. Pharmacotherapy. (2009) 10(1)
• Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross-over trial. Mov Disord. 2006 Jul 7; [Epub ahead of print] PMID: 16830315
• Subthalamic deep brain stimulation in patients with a previous pallidotomy. Ondo WG., Silay Y, Almaguer M, Jankovic J. Movement Disorders 2006[ PMID: 16673406]
• The lack of activity of Imatinib mesylate in small cell lung carcinoma expressing c-kit protein. Altundag O, Altundag K, Boruban C, Silay YS, Turen S. Cancer 2005 [PubMed - in process]
• Pure and mixed hormone receptor positive breast tumors: are they different from therapeutic point of view? Altundag K, Altundag O, Gunduz E, Silay YS, Boruban C. Medical Hypotheses 2005
• HER/2 neu intragenic kinase domain mutations may be a major determinant of response to trastuzamab or specific kinase inhibitors in non-small cell lung cancer patients. Ozden Altundag, Kadri Altundag, Bulent Ozcakar, Yavuz S. Silay Lung Cancer 2005 [PubMed - in process]
• Cross-Talk Between Cyclooxygenase-2 and Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer. Ozden Altundag, Kadri Altundag, Cem Boruban, Yavuz S. Silay Lung Cancer 2005
• Bisphosphonates may inhibit development of atherosclerosis formation through its bactericidal effect on nanobacteria. Yavuz S. Silay MD, CCRP, Kadri Altundag MD, Ozden Altundag MD, Mustafa A. Atik MD, Mustafa Ozen MD, PhD Medical Hypotheses 2005
• Botulinum Toxin Treatment for Oromandibular Dystonia and Bruxism in Patients with Tourette Syndrome Yavuz S. Silay M.D., Joseph Jankovic MD 57th Annual Meeting of the American Academy of Neurology Miami Beach, Florida Neurology Volume 65 P03.145 April 2005
• Emerging drugs in Tourette Syndrome Yavuz. S. Silay M.D., Joseph Jankovic MD Expert Opinion on Emerging Drugs 2005
• Parkinsonism associated with adalimumab in a patient with rheumatoid arthritis. Tintner R., Silay YS, Sessons S, Jankovic J. Mov Disord 2005;20(Suppl 10):S16.
• Intravenous Flumazenil for Parkinson’s Disease: A Double Blind, Placebo Controlled, Cross-Over Trial William G Ondo, MD, Yavuz S. Silay, MD (Platform presentation) Symposia on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders, October 3, 2004 Toronto, Ontario, Canada
• SRL172 (killed Mycobacterium vaccae ) may augment the efficacy of trastuzumab in metastatic breast cancer patients Kadri Altundag M.D., Ali-Seyed Mohamed, Ozden Altundag M.D. , Yavuz Selim Silay M.D., Esra Gunduz M.D., Kadir Demircan M.D. Medical Hypotheses. 2005;64(2):248-51. PMID: 15607548 [PubMed - in process]
• Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients. Altundag K, Silay YS, Altundag O, Yigitbasi OG, Gundeslioglu O, Gunduz M. Medical Hypotheses [PubMed - in process]
• The Safety of Deep Brain Stimulation in Patients with Patients with Parkinson’s Disease Essential Tremor and Other Movement Disorders Yavuz S. Silay, M.D., Joseph Jankovic, M.D. , Kevin D. Vuong, M.A. , Michael Almaguer, R.N. , William Ondo, M.D. , Ron Tintner, M.D. and Richard K. Simpson, M.D.,Ph.D.. 129th Annual Meeting of the American Neurological Association 7th Annual Neurology Outcomes Symposium, October 3-6, 2004 Toronto, Ontario, Canada published in Annals of Neurology Volume 56, Issue 6 S54 (Pages 916-926) ISSN: 1531-8249 (Online) ISSN: 0364-5134 (Print)
• Is Depression a Predictor of Outcome after Bilateral Subthalamic Deep Brain Stimulation in Patients with Parkinson’s Disease? Michele K. York, PhD, Yavuz S. Silay, M.D., Naomi S. Chaytor, M.S., Richard K. Simpson, M.D., Ph.D. , Joseph Jankovic, M.D. Movement Disorder Society's 8th International Congress of Parkinson's Disease and Movement Disorders June 13 - 17, 2004 Rome, Italy
• The efficacy and tolerability of fluphenazine in patients with tourette syndrome Yavuz S. Silay, M.D., Kevin D. Vuong,M.A., and Joseph Jankovic,M.D., Houston, Tx 4th International Scientific Symposium on Tourette Syndrome June 25-27 2004 Cleveland, Ohio
• Botulinum toxin treatment for oromandibular dystonia and bruxism with tourette syndrome Yavuz S. Silay, M.D., Joseph Jankovic,M.D., Houston, Tx 4th International Scientific Symposium on Tourette Syndrome June 25-27 Cleveland, Ohio
• The safety of deep brain stimulation in patients with Parkinson’s disese, essential tremor, and other movement disorders. Silay YS, Jankovic J, Vuong KD, Almageur M, Ondo W, Tintner R, Simpson RK. Ann Neurol 2004;56 (Suppl 8):S54-55
• The efficacy and safety of fluphenazine in patients with tourette syndrome Yavuz S. Silay, M.D., Kevin D. Vuong,M.A., and Joseph Jankovic,M.D., Houston, Tx, 56th Annual Meeting of the American Academy of Neurology San Francisco , California Neurology Volume 62 P06.128 April 2004 (Suppl 5)
• Calcium and Vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis Ozden Altundag M.D. Kadri Altundag M.D. Selim Silay Y M.D., Mehmet Gunduz M.D. PhD. , Kadir Demircan M.D. Ibrahim Gullu M.D. Medical Hypotheses 2004; 63(6):1010-1013 PMID: 15504568 [PubMed - in process]
• Evaluation of Tissue Injury Underlying Acute Traumatic Subdural Hematoma Roman Hlatky M.D., Maria Briones, M.D., Yavuz Silay M.D., Alex B. Valadka M.D., Claudia S. Robertson, M.D. Trauma & Critical Care [Article ID: 19675] American Association of Neurological Surgeons May 3 2004
• Significance of a reduced cerebral blood flow ultra-early after severe head injury Hlatky R, Silay YS, Praharaj S, Valadka AB, Robertson CS Young investigator Clinical Research Symposium 1;12 2002 (Entitled for Young Investigator Clinical Research Award by Baylor College of Medicine)
• Heterogeneity of Regional Cerebral Blood flow following severe head injury Galang M, Hlatky R, Praharaj S, Silay YS, Valadka AB, Robertson CS The Journal of Neurotrauma Volume 19 Number 10 P285 October 2002 ISSN:0897-7151
• Evaluation of cerebral circulatory arrest by (transcranial) ultrasonography Silay YS, Hlatky R, Praharaj SS, Galang M, Valadka AB, Robertson CS Young investigator Clinical Research Symposium 1;25 2002
• Dynamic Autoregulatory Response following severe head injury Hlatky R, Silay YS, Praharaj S , Valadka AB, Robertson CS Young investigator Clinical Research Symposium 1;11 2002
• Time Course of Brain Tissue Hypoxia in the penumbra region after trauma Roman Hlatky,Yavuz S. Silay,Shanti Praharaj,Maria C Briones-Galang, Alex B Valadka,Claudia S Robertson The Journal of Neurotrauma Volume 19 Number 10 P257 October 2002 ISSN:0897-7151
• Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross-over trial. Mov Disord. 2006 Jul 7; [Epub ahead of print] PMID: 16830315
• Subthalamic deep brain stimulation in patients with a previous pallidotomy. Ondo WG., Silay Y, Almaguer M, Jankovic J. Movement Disorders 2006[ PMID: 16673406]
• The lack of activity of Imatinib mesylate in small cell lung carcinoma expressing c-kit protein. Altundag O, Altundag K, Boruban C, Silay YS, Turen S. Cancer 2005 [PubMed - in process]
• Pure and mixed hormone receptor positive breast tumors: are they different from therapeutic point of view? Altundag K, Altundag O, Gunduz E, Silay YS, Boruban C. Medical Hypotheses 2005
• HER/2 neu intragenic kinase domain mutations may be a major determinant of response to trastuzamab or specific kinase inhibitors in non-small cell lung cancer patients. Ozden Altundag, Kadri Altundag, Bulent Ozcakar, Yavuz S. Silay Lung Cancer 2005 [PubMed - in process]
• Cross-Talk Between Cyclooxygenase-2 and Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer. Ozden Altundag, Kadri Altundag, Cem Boruban, Yavuz S. Silay Lung Cancer 2005
• Bisphosphonates may inhibit development of atherosclerosis formation through its bactericidal effect on nanobacteria. Yavuz S. Silay MD, CCRP, Kadri Altundag MD, Ozden Altundag MD, Mustafa A. Atik MD, Mustafa Ozen MD, PhD Medical Hypotheses 2005
• Botulinum Toxin Treatment for Oromandibular Dystonia and Bruxism in Patients with Tourette Syndrome Yavuz S. Silay M.D., Joseph Jankovic MD 57th Annual Meeting of the American Academy of Neurology Miami Beach, Florida Neurology Volume 65 P03.145 April 2005
• Emerging drugs in Tourette Syndrome Yavuz. S. Silay M.D., Joseph Jankovic MD Expert Opinion on Emerging Drugs 2005
• Parkinsonism associated with adalimumab in a patient with rheumatoid arthritis. Tintner R., Silay YS, Sessons S, Jankovic J. Mov Disord 2005;20(Suppl 10):S16.
• Intravenous Flumazenil for Parkinson’s Disease: A Double Blind, Placebo Controlled, Cross-Over Trial William G Ondo, MD, Yavuz S. Silay, MD (Platform presentation) Symposia on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders, October 3, 2004 Toronto, Ontario, Canada
• SRL172 (killed Mycobacterium vaccae ) may augment the efficacy of trastuzumab in metastatic breast cancer patients Kadri Altundag M.D., Ali-Seyed Mohamed, Ozden Altundag M.D. , Yavuz Selim Silay M.D., Esra Gunduz M.D., Kadir Demircan M.D. Medical Hypotheses. 2005;64(2):248-51. PMID: 15607548 [PubMed - in process]
• Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients. Altundag K, Silay YS, Altundag O, Yigitbasi OG, Gundeslioglu O, Gunduz M. Medical Hypotheses [PubMed - in process]
• The Safety of Deep Brain Stimulation in Patients with Patients with Parkinson’s Disease Essential Tremor and Other Movement Disorders Yavuz S. Silay, M.D., Joseph Jankovic, M.D. , Kevin D. Vuong, M.A. , Michael Almaguer, R.N. , William Ondo, M.D. , Ron Tintner, M.D. and Richard K. Simpson, M.D.,Ph.D.. 129th Annual Meeting of the American Neurological Association 7th Annual Neurology Outcomes Symposium, October 3-6, 2004 Toronto, Ontario, Canada published in Annals of Neurology Volume 56, Issue 6 S54 (Pages 916-926) ISSN: 1531-8249 (Online) ISSN: 0364-5134 (Print)
• Is Depression a Predictor of Outcome after Bilateral Subthalamic Deep Brain Stimulation in Patients with Parkinson’s Disease? Michele K. York, PhD, Yavuz S. Silay, M.D., Naomi S. Chaytor, M.S., Richard K. Simpson, M.D., Ph.D. , Joseph Jankovic, M.D. Movement Disorder Society's 8th International Congress of Parkinson's Disease and Movement Disorders June 13 - 17, 2004 Rome, Italy
• The efficacy and tolerability of fluphenazine in patients with tourette syndrome Yavuz S. Silay, M.D., Kevin D. Vuong,M.A., and Joseph Jankovic,M.D., Houston, Tx 4th International Scientific Symposium on Tourette Syndrome June 25-27 2004 Cleveland, Ohio
• Botulinum toxin treatment for oromandibular dystonia and bruxism with tourette syndrome Yavuz S. Silay, M.D., Joseph Jankovic,M.D., Houston, Tx 4th International Scientific Symposium on Tourette Syndrome June 25-27 Cleveland, Ohio
• The safety of deep brain stimulation in patients with Parkinson’s disese, essential tremor, and other movement disorders. Silay YS, Jankovic J, Vuong KD, Almageur M, Ondo W, Tintner R, Simpson RK. Ann Neurol 2004;56 (Suppl 8):S54-55
• The efficacy and safety of fluphenazine in patients with tourette syndrome Yavuz S. Silay, M.D., Kevin D. Vuong,M.A., and Joseph Jankovic,M.D., Houston, Tx, 56th Annual Meeting of the American Academy of Neurology San Francisco , California Neurology Volume 62 P06.128 April 2004 (Suppl 5)
• Calcium and Vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis Ozden Altundag M.D. Kadri Altundag M.D. Selim Silay Y M.D., Mehmet Gunduz M.D. PhD. , Kadir Demircan M.D. Ibrahim Gullu M.D. Medical Hypotheses 2004; 63(6):1010-1013 PMID: 15504568 [PubMed - in process]
• Evaluation of Tissue Injury Underlying Acute Traumatic Subdural Hematoma Roman Hlatky M.D., Maria Briones, M.D., Yavuz Silay M.D., Alex B. Valadka M.D., Claudia S. Robertson, M.D. Trauma & Critical Care [Article ID: 19675] American Association of Neurological Surgeons May 3 2004
• Significance of a reduced cerebral blood flow ultra-early after severe head injury Hlatky R, Silay YS, Praharaj S, Valadka AB, Robertson CS Young investigator Clinical Research Symposium 1;12 2002 (Entitled for Young Investigator Clinical Research Award by Baylor College of Medicine)
• Heterogeneity of Regional Cerebral Blood flow following severe head injury Galang M, Hlatky R, Praharaj S, Silay YS, Valadka AB, Robertson CS The Journal of Neurotrauma Volume 19 Number 10 P285 October 2002 ISSN:0897-7151
• Evaluation of cerebral circulatory arrest by (transcranial) ultrasonography Silay YS, Hlatky R, Praharaj SS, Galang M, Valadka AB, Robertson CS Young investigator Clinical Research Symposium 1;25 2002
• Dynamic Autoregulatory Response following severe head injury Hlatky R, Silay YS, Praharaj S , Valadka AB, Robertson CS Young investigator Clinical Research Symposium 1;11 2002
• Time Course of Brain Tissue Hypoxia in the penumbra region after trauma Roman Hlatky,Yavuz S. Silay,Shanti Praharaj,Maria C Briones-Galang, Alex B Valadka,Claudia S Robertson The Journal of Neurotrauma Volume 19 Number 10 P257 October 2002 ISSN:0897-7151
links
publications
Sizes of these terms reflect their relevance to your search.
The balance between immunosuppression to ensure graft tolerance while preventing emergence of infectious complications is key in lung transplantation. Although opportunistic infection may appear to be the most important of these complications, malignancies…
Expert opinion on emerging drugs. 2007 Mar
Flumazenil is a short-acting intravenously administered gamma-aminobutyric acid (GABA) antagonist used to reverse the effects of benzodiazepines. Based upon current basal ganglion models in Parkinson's disease (PD), flumazenil could normalize neuronal sign…
Movement disorders : official journal of the Movement Disorder Society. 2006 Oct
Medical hypotheses. 2006
Cancer. 2005 Nov 1
Lung cancer (Amsterdam, Netherlands). 2005 Sep
Medical hypotheses. 2006
Lung cancer (Amsterdam, Netherlands). 2005 Aug
Proper education of the patient is the first step in the treatment of Tourette syndrome (TS). Before deciding how to treat the patient, it is important to decide whether to treat the TS-related symptoms. Counselling and behavioural modification may be suff…
Expert opinion on emerging drugs. 2005 May
Medical hypotheses. 2005
Medical hypotheses. 2005
Recently, cyclooxygenase-2 (COX-2) inhibitor therapy has emerged as a possible new approach to the prevention and treatment of colorectal cancer (CRC). The COX enzymes (COX-1 and COX-2) are key enzymes of prostaglandin (PG) biosynthesis and are overexpress…
Medical hypotheses. 2005
